Overview
Paul Radensky, who represented clinical laboratory stakeholder groups in negotiating new Medicare reimbursement rules, said that the labs “will have to consider carefully before they simply accept rates that are tied to a certain percentage of Medicare” under the rules, but added that the 2017 implementation date for market-based pricing will “give labs some time to factor the law into their discussions with private payers.” Read the full article
